4023 CapSure SP |
Product Characteristics | |||
|---|---|---|---|---|
| US Market Release | Aug-91 | Serial Number Prefix | LAK | |
| Registered US Implants | 41,200 | Type and/or Fixation | Transvenous, Vent., Tines | |
| Estimated Active US Implants | 9,600 | Polarity | Unipolar | |
| Advisories | None | Steroid | Yes | |
| Ventricular Placement | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| System Longevity Study Results |
|
|||||||||
| Number of Leads Enrolled in Study | 1,158 | |||||||||
| Cumulative Months of Follow-Up | 65,853 | |||||||||
| Number of Leads Active in Study | 341 | |||||||||
| Qualifying Complications | 20 Total | |||||||||
| Extra Cardiac Stimulation | 1 | |||||||||
| Failure to Capture | 15 | |||||||||
| Impedance Out of Range | 1 | |||||||||
| Insulation (not further defined) | 1 | |||||||||
| Lead Dislodgement | 2 | |||||||||
